Ally Olotu is KEMRI-Wellcome Trust affiliate and works with Ifakara Health Institute in Bagamoyo, Tanzania. He has an MD degree from University of Dar es salaam and DPhil in clinical epidemiology and vaccinology from University of Oxford, UK. His interest is in malaria epidemiology and clinical trials that investigate the safety, immunogenicity and public health utility of interventions in low and middle income countries (LMICs). Emerging interest include improvement of quality of clinical care in public health facilities. In 2005, he received WHO/TDR Career Development Fellowship in Malaria Vaccine Development at GSK Biologicals in Rixensart, Belgium and WHO/TDR headquarters in Geneva, Switzerland. His contribution has been on investigation of long-term efficacy of RTS,S candidate malaria vaccine in young children living in a malaria endemic country, describing its interaction with malaria exposure and study the correlates of immune protection in children who received RTS,S vaccine in Kenya. In 2013 he won the Oxford University Nuffield Department of Medicine Graduate Research Prize for his DPhil work. He also coordinated the first ever clinical trials in the history of Equatorial Guinea, evaluating the safety and efficacy of Sanaria’s PfSPZ Vaccine.
Ally is the currently an MRC African Research Leader Fellow, working with Prof Simon Draper from University of Oxford, UK to evaluate the safety and immunogenicity of a candidate blood stage vaccine, reticulocyte-binding protein homologue 5 (RH5) in Bagamoyo, Tanzania. He is also collaborating with Prof Philip Bejon and Mainga Hamaluba from KEMRI-Wellcome Trust Research Program, Sanaria and Swiss Tropical Public Health Institute.